GGPPS

By Targets:	Akt (1) Apoptosis (3) Calcineurin (1) Calcium Channel (4) Endogenous Metabolite (5) Farnesyl Transferase (2) GCGR (2) GLP Receptor (2) HMG-CoA Reductase (HMGCR) (1) Isotope-Labeled Compounds (2) Parasite (1) PI3K (1) Ras (3) Small Interfering RNA (siRNA) (2) TRP Channel (5)
By Research Areas:	Cancer (9) Infection (1) Inflammation/Immunology (6) Metabolic Disease (3) Neurological Disease (5)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113037C

Farnesyl pyrophosphate ammonium Farnesyl diphosphate ammonium	TRP Channel Endogenous Metabolite Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
Farnesyl pyrophosphate (Farnesyl diphosphate) ammonium is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate ammonium is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate ammonium is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases .

HY-U00145

Digeranyl bisphosphonate 3 Publications Verification DGBP	Ras	Inflammation/Immunology
Digeranyl bisphosphonate (DGBP) is a potent geranylgeranylpyrophosphate (GGPP) synthase inhibitor, which inhibits geranylgeranylation of Rac1.

HY-113037

(E/Z)-Farnesyl pyrophosphate (E/Z)-Farnesyl diphosphate	TRP Channel Endogenous Metabolite	Neurological Disease
(E/Z)-Farnesyl pyrophosphate ((E/Z)-Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. (E/Z)-Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. (E/Z)-Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .

HY-135700

Mevalonolactone	Calcineurin Ras HMG-CoA Reductase (HMGCR)	Metabolic Disease Inflammation/Immunology
Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (K_a = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the *GGPPS* promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy .

HY-P10031

SAR441255	GLP Receptor GCGR	Metabolic Disease
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-113037CS

Farnesyl pyrophosphate-d2 triammonium Farnesyl diphosphate-d2 triammonium	Isotope-Labeled Compounds TRP Channel Endogenous Metabolite Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
Farnesyl pyrophosphate-d₂ (Farnesyl diphosphate-d₂) triammonium is a deuterium labeled Farnesyl pyrophosphate triammonium (HY-113037C). Farnesyl pyrophosphate ammonium is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate ammonium is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate ammonium is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.

HY-113037B

Farnesyl pyrophosphate Farnesyl diphosphate	TRP Channel Endogenous Metabolite Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
Farnesyl pyrophosphate is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.

HY-113752

MMV019313	Parasite	Infection
MMV019313 is a potent, non-bisphosphonate inhibitor of farnesyl/geranylgeranyl diphosphate synthase (FPPS/GGPPS) with an IC₅₀ of 0.82 µM. MMV019313 has activity against P. falciparum (Parasite) .

HY-113037AS

Farnesyl pyrophosphate-d6 Farnesyl diphosphate-d₆	Isotope-Labeled Compounds TRP Channel Endogenous Metabolite Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
Farnesyl pyrophosphate-d₆ (Farnesyl diphosphate-d₆) is a deuterium labeled Farnesyl pyrophosphate (HY-113037B). Farnesyl pyrophosphate is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.

HY-P10031A

SAR441255 TFA	GLP Receptor GCGR	Metabolic Disease
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors.?SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-136829

BPH-675	Apoptosis	Others
BPH-675 is a large bisphosphonate inhibitor with long hydrophobic side chains and a potent and selective geranylgeranyl diphosphate synthase (GGPPS) inhibitor with an IC₅₀ of 0.71 μM. GGPPS inhibitor promotes HUVEC apoptosis .

HY-RS05402

GGPS1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
GGPS1 Human Pre-designed siRNA Set A contains three designed siRNAs for GGPS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

GGPS1 Human Pre-designed siRNA Set A GGPS1 Human Pre-designed siRNA Set A

HY-124723

Gerfelin	Farnesyl Transferase	Cancer
Gerfelin inhibits *geranylgeranyl diphosphate synthase (GGPP* synthase) activity with an IC₅₀** of 3.5 μg/mL .

HY-113869

BPH-628	Apoptosis PI3K Akt	Cancer
BPH-628 is an aromatic geranylgeranyl diphosphate synthase (GGPPS) inhibitor, with a pIC₅₀ of 6.1 .

HY-113793

BPH-742	Ras	Cancer
BPH-742 (compound 9) is a Geranylgeranyl diphosphate synthase inhibitor with IC₅₀ of 0.1 μM. BPH-742 has antitumor activity .

HY-RS19684

Ggps1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ggps1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ggps1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ggps1 Mouse Pre-designed siRNA Set A Ggps1 Mouse Pre-designed siRNA Set A

HY-126472

BPH252	Farnesyl Transferase	Cancer
BPH252 (Compound 4) is a geranylgeranyl diphosphate synthase inhibitor. BPH252 can be used in research on bisphosphonate-based anticancer inhibitors .

HY-186013

CML-07-119	Apoptosis	Cancer
CML-07-119 is a selective inhibitor of GGPP synthase (GGPPS) with an IC₅₀ of ~27 nM. CML-07-119 induces apoptosis and exhibits anticancer activity against acute myeloid leukemia (AML) cells, including those harbouring TP53 mutations. CML-07-119 inhibits tumor growth in an AML mouse xenograft model. CML-07-119 can be used for AML research .

Cat. No.	Product Name	Target	Research Area

HY-P10031

SAR441255	GLP Receptor GCGR	Metabolic Disease
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-P10031A

SAR441255 TFA	GLP Receptor GCGR	Metabolic Disease
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors.?SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113037C

Farnesyl pyrophosphate ammonium Farnesyl diphosphate ammonium	Natural Products Neurological Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	TRP Channel Endogenous Metabolite Calcium Channel
Farnesyl pyrophosphate (Farnesyl diphosphate) ammonium is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate ammonium is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate ammonium is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases .

HY-113037

(E/Z)-Farnesyl pyrophosphate (E/Z)-Farnesyl diphosphate	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Neurological Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	TRP Channel Endogenous Metabolite
(E/Z)-Farnesyl pyrophosphate ((E/Z)-Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. (E/Z)-Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. (E/Z)-Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .

HY-135700

Mevalonolactone	Structural Classification Microorganisms Other Phenylpropanoids Phenylpropanoids Source Classification	Calcineurin Ras HMG-CoA Reductase (HMGCR)
Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (K_a = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the *GGPPS* promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy .

HY-124723

Gerfelin	Microorganisms Antibiotics Other Antibiotics Source Classification	Farnesyl Transferase
Gerfelin inhibits *geranylgeranyl diphosphate synthase (GGPP* synthase) activity with an IC₅₀** of 3.5 μg/mL .

Cat. No.	Product Name	Chemical Structure

HY-113037CS

Farnesyl pyrophosphate-d2 triammonium
Farnesyl pyrophosphate-d₂ (Farnesyl diphosphate-d₂) triammonium is a deuterium labeled Farnesyl pyrophosphate triammonium (HY-113037C). Farnesyl pyrophosphate ammonium is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate ammonium is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate ammonium is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.

Farnesyl pyrophosphate-d2 triammonium

Farnesyl pyrophosphate-d₂ (Farnesyl diphosphate-d₂) triammonium is a deuterium labeled Farnesyl pyrophosphate triammonium (HY-113037C). Farnesyl pyrophosphate ammonium is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate ammonium is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate ammonium is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.

HY-113037AS

Farnesyl pyrophosphate-d6
Farnesyl pyrophosphate-d₆ (Farnesyl diphosphate-d₆) is a deuterium labeled Farnesyl pyrophosphate (HY-113037B). Farnesyl pyrophosphate is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.

Farnesyl pyrophosphate-d6

Farnesyl pyrophosphate-d₆ (Farnesyl diphosphate-d₆) is a deuterium labeled Farnesyl pyrophosphate (HY-113037B). Farnesyl pyrophosphate is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.

Host:	Mouse (2)
Reactivity:	Human (2) Rat (2) Mouse (2)
Application:	IHC-P (2)
Isotype:	IgG1 (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (1)
Modification:	Unmodified (1)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P88280

	GGPS1 Antibody (YA7964) GGPPS; GGPPS1	IHC-P	Human, Mouse, Rat
	GGPS1 Antibody (YA7964) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GGPS1.

HY-P88280A

	GGPS1 Antibody (YA7964)(PBS only) GGPPS; GGPPS1	IHC-P	Human, Mouse, Rat
	GGPS1 Antibody (YA7964) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GGPS1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-RS05402

GGPS1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
GGPS1 Human Pre-designed siRNA Set A contains three designed siRNAs for GGPS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS19684

Ggps1 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Ggps1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ggps1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides